Endocrine-Disrupting Chemicals Linked to Diabetes Disparities

Share this content:
Endocrine-Disrupting Chemicals Linked to Diabetes Disparities
Endocrine-Disrupting Chemicals Linked to Diabetes Disparities

WEDNESDAY, Nov. 29, 2017 (HealthDay News) -- Disparities in exposure to diabetes-associated environmental endocrine-disrupting chemicals (EDCs) may contribute to disparities in diabetes, according to a review published online Nov. 15 in Diabetes Care.

Noting that disproportionate exposure to diabetes-associated EDCs may be an underappreciated contributor to disparities in metabolic disease risk, Daniel Ruiz, from the University of Chicago, and colleagues reviewed the evidence linking unequal exposures to EDCs with racial, ethnic, and socioeconomic diabetes disparities in the United States. Data were obtained from articles that examined the correlation between chemical exposures and metabolic disease. EDCs that were associated with diabetes in the literature were further assessed for evidence of racial, ethnic, and socioeconomic exposure disparities.

The researchers found that numerous studies reported significantly higher exposures to diabetogenic EDCs -- including polychlorinated biphenyls, organochlorine pesticides, multiple chemical constituents of air pollution, bisphenol A, and phthalates -- among Latinos, African-Americans, and low-income individuals.

"This review reveals that unequal exposure to EDCs may be a novel contributor to diabetes disparities," the authors write. "Efforts to reduce the individual and societal burden of diabetes should include educating clinicians on environmental exposures that may increase disease risk, strategies to reduce those exposures, and social policies to address environmental inequality as a novel source of diabetes disparities."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab + Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »